Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | STS | P08842 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.45 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.45 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.45 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20632691 | 0.94 | PDE4B (0.49) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3316022 | 0.89 | PDE4B (0.43) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4402806 | 0.88 | GPR119 (0.54) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL214982 | 0.87 | GPR119 (0.55) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL25725919 | 0.87 | PDE4D (0.51) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL217021 | 0.86 | GPR119 (0.54) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2491113 | 0.86 | GPR119 (0.63) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30043078 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HRH3LMNAMAPTHTT | |
| SCHEMBL1447329 | 0.85 | GPR119 (0.54) | GPR119PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL21633387 | 0.84 | GPR119 (0.53) | GPR119PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| CN-114929675-B | Adamantane derivatives as focal adhesion kinase inhibitors | 三进制药株式会社 | 2024-02-13 | — | — | CN | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | INCHEON NATIONAL UNIVERSITY RESEARCH & BUSINESS FOUNDATION (KR) | 2023-02-16 | — | — | US | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| EP-4074697-A2 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | Samjin Pharmaceutical Co., Ltd. (KR) | 2022-10-19 | — | — | EP | disclosed |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2022-08-23 | — | — | US | disclosed |
| CN-114929675-A | Novel adamantane derivatives as inhibitors of focal adhesion kinase | 三进制药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-114042070-A | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-02-15 | — | — | CN | disclosed |
| CN-108137544-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XW LABORATORIES INC. (KY) | 2020-04-14 | — | — | US | disclosed |
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-04-02 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102289-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | GPR119 119/4885PDE4B 1442/4885PDE4A 1279/4885 |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | GPR119 2753/4885PDE4B 1200/4885PDE4A 1590/4885 |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | GPR119 73/4885PDE4B 1287/4885PDE4A 1304/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | GPR119 2753/4885PDE4B 1200/4885PDE4A 1590/4885 |
| US-10618886-B1 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | GPR119 119/4885PDE4B 1442/4885PDE4A 1279/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | GPR119 119/4885PDE4B 1442/4885PDE4A 1279/4885 |
| US-20230049557-A1 | NOVEL ADAMANTANE DERIVATIVES AS INHIBITORS OF FOCAL ADHESION KINASE | PTK2, DAPK2, DAPK1 | GPR119 2931/4885PDE4B 1494/4885PDE4A 1310/4885 |
| US-11420955-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | GPR119 119/4885PDE4B 1442/4885PDE4A 1279/4885 |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | GPR119 365/4885PDE4B 305/4885PDE4A 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.